Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06941376 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis
A Phase 2 study of Relapsing Polychondritis, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06941376 is a Phase 2 study of Relapsing Polychondritis that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 20 participants, below the 1,368-participant average among 3 other Relapsing Polychondritis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06941376, a Phase 2 study of Relapsing Polychondritis, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).
Conditions Studied
Interventions
- DRUG Methotrexate (MTX)
- DRUG Azathioprine (AZA)
- BIOLOGICAL Adalimumab
- BIOLOGICAL Infliximab
- BIOLOGICAL Tocilizumab
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06941376
The ClinicalTrials.gov registry entry for NCT06941376 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,368-participant average among 3 other Relapsing Polychondritis trials with a reported enrollment target (99% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Polychondritis appearing as the primary indexed condition, and to 5 interventions - of which Methotrexate (MTX) is the first listed.
NCT06941376 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06941376 about?
NCT06941376 is a clinical study titled "An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis". Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).
What is the current status of trial NCT06941376?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-08-01. Estimated completion is 2027-12.
What conditions does trial NCT06941376 study?
This clinical trial studies the following conditions: Relapsing Polychondritis.
What interventions are being tested in trial NCT06941376?
The interventions under investigation include: Methotrexate (MTX) (DRUG), Azathioprine (AZA) (DRUG), Adalimumab (BIOLOGICAL), Infliximab (BIOLOGICAL), Tocilizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06941376?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06941376 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Polychondritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.